[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Myers et al., 2003 - Google Patents

The rate of fibrosis progression is an independent predictor of the response to antiviral therapy in chronic hepatitis C

Myers et al., 2003

Document ID
15585106986049989137
Author
Myers R
Patel K
Pianko S
Poynard T
McHutchison J
Publication year
Publication venue
Journal of Viral Hepatitis

External Links

Snippet

The response to antiviral therapy and the rate of fibrosis progression in chronic hepatitis C virus (HCV) infection are related to common factors, including age and gender. The aim of this study was to evaluate the relationship between the rate of fibrosis progression and the …
Continue reading at onlinelibrary.wiley.com (other versions)

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay
    • G01N33/576Immunoassay; Biospecific binding assay for hepatitis
    • G01N33/5767Immunoassay; Biospecific binding assay for hepatitis non-A, non-B hepatitis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriphage
    • C12Q1/701Specific hybridization probes
    • C12Q1/706Specific hybridization probes for hepatitis
    • C12Q1/707Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D

Similar Documents

Publication Publication Date Title
Myers et al. The rate of fibrosis progression is an independent predictor of the response to antiviral therapy in chronic hepatitis C
Kalantar-Zadeh et al. Hepatitis C virus and death risk in hemodialysis patients
Imazeki et al. Prevalence of diabetes mellitus and insulin resistance in patients with chronic hepatitis C: comparison with hepatitis B virus‐infected and hepatitis C virus‐cleared patients
Chemello et al. Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-α in chronic hepatitis C
Seeff et al. 45-year follow-up of hepatitis C virus infection in healthy young adults
Rao et al. Distribution and clinical correlates of viral and host genotypes in C hinese patients with chronic hepatitis C virus infection
Miyaki et al. Daclatasvir and asunaprevir treatment improves liver function parameters and reduces liver fibrosis markers in chronic hepatitis C patients
Booth et al. Clinical guidelines on the management of hepatitis C
Alazawi et al. Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection
Enomoto et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection
Park et al. High prevalence of significant histology in asymptomatic chronic hepatitis B patients with genotype C and high serum HBV DNA levels
Pardo et al. Comparative study between occult hepatitis C virus infection and chronic hepatitis C
Pradat et al. Long‐term follow‐up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liver‐related complications
HUANG et al. Sustained virological response to interferon reduces cirrhosis in chronic hepatitis C: a 1386‐patient study from Taiwan
Kamal et al. Enhanced efficacy of pegylated interferon alpha‐2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis
Kosaka et al. Emergence of resistant variants detected by ultra‐deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1
Yu et al. A randomized trial of 24‐vs. 48‐week courses of PEG interferon α‐2b plus ribavirin for genotype‐1b‐infected chronic hepatitis C patients: a pilot study in Taiwan
Nguyen et al. Response to pegylated interferon and ribavirin in Asian American patients with chronic hepatitis C genotypes 1 vs 2/3 vs 6
Papatheodoridis et al. Impact of interferon‐alpha therapy on liver fibrosis progression in patients with HBeAg‐negative chronic hepatitis B
Hsu et al. Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis‐related complications (Taiwanese chronic hepatitis C cohort)
Hung et al. Anemia associated with antiviral therapy in chronic hepatitis C: incidence, risk factors, and impact on treatment response
Lao et al. Sex and age differences in lipid response to chronic infection with the hepatitis C virus in the United States National Health and Nutrition Examination Surveys
YEN et al. Mutations in the interferon sensitivity‐determining region (nonstructural 5A amino acid 2209–2248) in patients with hepatitis C‐1b infection and correlating response to combined therapy of pegylated interferon and ribavirin
Bonny et al. Effectiveness of interferon plus ribavirin combination in the treatment of naive patients with hepatitis C virus type 5. A French multicentre retrospective study
Kenny-Walsh The natural history of hepatitis C virus infection